RGRebecca M. Gardner

Rebecca M. Gardner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rebecca M. Gardner has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trends in prevalence and treatment of antepartum and postpartum depression in the United States: Data from the national health and nutrition examination survey (NHANES) 2007 to 2018

    by Rebecca M. Gardner, Pervez Sultan, Rebecca A. Bernert, Julia F. Simard

    Objectives: (1) To assess the prevalence of depression and treatment rates in antepartum and postpartum women compared to a control group of reproductive-age women over a 12-year period, and (2) To determine demographic characteristics associated with depression. Methods: National Health and Nutrition Examination Survey data (2007–2018) were used. 5412 controls, 314 antepartum women, and 455 postpartum women were analyzed. Outcomes included depression prevalence, defined as moderate to severe depressive symptoms measured by Patient Health Questionnaire-9 (PHQ-9) scores ≥10 or self-reported antidepressant use; and treatment, defined as antidepressant prescription and/or mental health care services in the past 12 months. Multivariable logistic regression adjusted for age, insurance, race/ethnicity, education, and marital status estimated odds ratios and 95% confidence intervals. Results: Depression prevalence was 20.2% in controls (95% CI 18.5–21.9), 9.7% in antepartum (6.3–14.1), and 12.8% in postpartum women (9.3–17.1). Mental health care service utilization increased for postpartum women in 2017–2018 (22.0%, 10.6–37.7). In those with depression, control and postpartum groups had similar treatment rates (70%, p = 0.894) compared to antepartum women (51%, p = 0.051). Antidepressant use was the most common treatment reported in all groups. Those who were married or had private insurance had the lowest depression rates in their respective categories. After adjusting for confounders, antepartum and postpartum women had lower odds of depression compared to controls. When the outcome was PHQ-9 ≥ 10 alone, these associations persisted. Conclusion: In a nationally representative sample, depression prevalence was lower in perinatal women compared to reproductive-age controls, and treatment rates were lowest in antepartum women with prevalent depression. Mental health care services may have increased for postpartum women due to the US Preventive Services Task Force 2016 recommendations, which endorsed psychotherapy for postpartum women. Even so, antidepressants were the most reported treatment among perinatal women, despite psychotherapy being the first-line recommended treatment for this population.


  • Open Access

    The development of a mobile app‐focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials

    by Ariadna Garcia, Justin Lee, Vidhya Balasubramanian, Rebecca Gardner, Santosh E. Gummidipundi, Grace Hung, Todd Ferris, Lauren Cheung, Sumbul Desai, Christopher B. Granger, et al.

    An app‐based clinical trial enrolment process can contribute to duplicated records, carrying data management implications. Our objective was to identify duplicated records in real time in the Apple Heart Study (AHS). We leveraged personal identifiable information (PII) to develop a dissimilarity score (DS) using the Damerau–Levenshtein distance. For computational efficiency, we focused on four types of records at the highest risk of duplication. We used the receiver operating curve (ROC) and resampling methods to derive and validate a decision rule to classify duplicated records. We identified 16,398 (4%) duplicated participants, resulting in 419,297 unique participants out of a total of 438,435 possible. Our decision rule yielded a high positive predictive value (96%) with negligible impact on the trial's original findings. Our findings provide principled solutions for future digital trials. When establishing deduplication procedures for digital trials, we recommend collecting device identifiers in addition to participant identifiers; collecting and ensuring secure access to PII; conducting a pilot study to identify reasons for duplicated records; establishing an initial deduplication algorithm that can be refined; creating a data quality plan that informs refinement; and embedding the initial deduplication algorithm in the enrolment platform to ensure unique enrolment and linkage to previous records.


  • Continuity of Care in Primary Care for Young Children With Chronic Conditions

    by Yair Bannett, Rebecca M. Gardner, Lynne C. Huffman, Heidi M. Feldman, Lee M. Sanders


  • Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer

    by Jessica A. Hellyer, Maya N. White, Rebecca M. Gardner, Kristen Cunanan, Sukhmani K. Padda, Millie Das, Kavitha Ramchandran, Joel W. Neal, Heather A. Wakelee


  • Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib

    by Maya N. White, Andrew J Piper-Vallillo, Rebecca M. Gardner, Kristen Cunanan, Joel W. Neal, Millie Das, Sukhmani K. Padda, Kavitha Ramchandran, Thomas T. Chen, Lecia V. Sequist, et al.


  • Open Access

    Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer

    by Eunji Choi, Nilotpal Sanyal, Victoria Y Ding, Rebecca M Gardner, Jacqueline V Aredo, Justin Lee, Julie T Wu, Thomas P Hickey, Brian Barrett, Thomas L Riley, et al.

    With advancing therapeutics, lung cancer (LC) survivors are rapidly increasing in number. Although mounting evidence suggests LC survivors have high risk of second primary lung cancer (SPLC), there is no validated prediction model available for clinical use to identify high-risk LC survivors for SPLC. Using data from 6325 ever-smokers in the Multiethnic Cohort (MEC) study diagnosed with initial primary lung cancer (IPLC) in 1993-2017, we developed a prediction model for 10-year SPLC risk after IPLC diagnosis using cause-specific Cox regression. We evaluated the model’s clinical utility using decision curve analysis and externally validated it using 2 population-based data—Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) and National Lung Screening Trial (NLST)—that included 2963 and 2844 IPLC (101 and 93 SPLC cases), respectively. Over 14 063 person-years, 145 (2.3%) ever-smoking IPLC patients developed SPLC in MEC. Our prediction model demonstrated a high predictive accuracy (Brier score = 2.9, 95% confidence interval [CI] = 2.4 to 3.3) and discrimination (area under the receiver operating characteristics [AUC] = 81.9%, 95% CI = 78.2% to 85.5%) based on bootstrap validation in MEC. Stratification by the estimated risk quartiles showed that the observed SPLC incidence was statistically significantly higher in the 4th vs 1st quartile (9.5% vs 0.2%; P < .001). Decision curve analysis indicated that in a wide range of 10-year risk thresholds from 1% to 20%, the model yielded a larger net-benefit vs hypothetical all-screening or no-screening scenarios. External validation using PLCO and NLST showed an AUC of 78.8% (95% CI = 74.6% to 82.9%) and 72.7% (95% CI = 67.7% to 77.7%), respectively. We developed and validated a SPLC prediction model based on large population-based cohorts. The proposed prediction model can help identify high-risk LC patients for SPLC and can be incorporated into clinical decision making for SPLC surveillance and screening.


  • Open Access

    Pregnancy success rates for lesbian women undergoing intrauterine insemination

    by Jasmyn K. Johal, Rebecca M. Gardner, Sara J. Vaughn, Eleni G. Jaswa, Haley Hedlin, Lusine Aghajanova


  • A rapid echocardiographic screening protocol for rheumatic heart disease in Samoa: a high prevalence of advanced disease

    by Marvin Allen, John Allen, Take Naseri, Rebecca Gardner, Dennis Tolley, Lori Allen

    Background Echocardiography has been proposed as a method to screen children for rheumatic heart disease. The World Heart Federation has established guidelines for echocardiographic screening. In this study, we describe a rapid echocardiogram screening protocol according to the World Heart Federation guidelines in Samoa, endemic for rheumatic heart disease. Methods We performed echocardiogram screening in schoolchildren in Samoa between 2013 and 2015. A brief screening echocardiogram was performed on all students. Children with predefined criteria suspicious for rheumatic hear diseases were referred for a more comprehensive echocardiogram. Complete echocardiograms were classified according to the World Heart Federation guidelines and severity of valve disease. Results Echocardiographic screening was performed on 11,434 children, with a mean age of 10.2 years; 51% of them were females. A total of 558 (4.8%) children underwent comprehensive echocardiography, including 49 students who were randomly selected as controls. Definite rheumatic heart disease was observed in 115 students (10.0 per 1000): 92 students were classified as borderline (8.0 per 1000) and 23 with CHD. Advanced disease was identified in 50 students (4.4 per 1000): 15 with severe mitral regurgitation, five with severe aortic regurgitation, 11 with mitral stenoses, and 19 with mitral and aortic valve disease. Conclusions We successfully applied a rapid echocardiographic screening protocol to a large number of students over a short time period – 28 days of screening over a 3-year time period – to identify a high prevalence of rheumatic heart disease. We also reported a significantly higher rate of advanced disease compared with previously published echocardiographic screening programmes.